This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold

Sponsored by Brainfarma Industria Química e Farmacêutica S/A

About this trial

Last updated 9 years ago

Study ID

Coristina® d

Status

Unknown status

Type

Interventional

Phase

Phase 3

Placebo

No

Accepting

18-75 Years
18 to 60 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 8 years ago

What is this trial about?

The primary objective of this study is to evaluate the non-inferiority of Coristina® d in the symptomatic treatment of the common cold compared to Resfenol® comparator.

What are the participation requirements?

Yes

Inclusion Criteria

1. Sign and date the informed consent form;

2. Age between 18 and 60 years old;

3. Symptoms of common cold not exceeding 72 hours must be present;

4. It will be considered symptoms of the common cold the presence of at least 2 of the 10 symptoms following: runny nose, sneezing, nasal congestion, headache, myalgia, throat discomfort or sore throat, hoarseness, cough or fever. Each of the symptoms listed above will receive a score by Likert scale (no symptom = 0, mild symptoms = 1, moderate symptoms = 2, intense symptoms = 3). The minimum total is 0 and maximum one is 30, which included patients with score higher or equal to 4 points.

No

Exclusion Criteria

1. Presence of suggestive symptoms or prior diagnosis requiring regular and continuous treatment of allergic rhinitis or asthma in the last 2 years;

2. Chronic disease of any kind that is contraindicate the participation of the patient based on the opinion of investigator;

3. Hypersensitivity or contraindication to use of components of the study medications;

4. Pregnant or women of childbearing age without adequate contraception;

5. Use of other anti-influenza drugs programmed during the study or for the last 5 days;

6. Regular active smokers (more than 3 cigarettes a day);

7. Participation in another clinical study in less than one year (unless justified benefit by the investigator).